Royal Bank Of Canada Protagonist Therapeutics, Inc Transaction History

Royal Bank Of Canada

$458 Billion
Q1 2025

A detailed history of Royal Bank Of Canada transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 9,964 shares of PTGX stock, worth $444,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,964

Previous 7,630 30.59%

Holding current value

$444,294

Previous $294,000 63.61%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$35.09 - $59.76 $81,900 - $139,479	2,334 Added 30.59%	9,964 $481,000
Q4 2024 Feb 14, 2025	SELL	$38.51 - $48.43 $228,479 - $287,335	-5,933 Reduced 43.74%	7,630 $294,000
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $112,658 - $158,129	3,341 Added 32.68%	13,563 $609,000
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $112,030 - $158,096	4,543 Added 80.0%	10,222 $354,000
Q1 2024 Nov 05, 2024	SELL	$21.79 - $32.15 $98,991 - $146,057	-4,543 Reduced 44.44%	5,679 $164,000
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $256,599 - $378,598	-11,776 Reduced 67.46%	5,679 $164,000
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $132,013 - $220,242	9,396 Added 116.59%	17,455 $400,000
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $64,084 - $90,901	3,842 Added 91.11%	8,059 $134,000
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $28,525 - $46,476	1,583 Added 60.1%	4,217 $116,000
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $31,359 - $73,830	-2,909 Reduced 52.48%	2,634 $60,000
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $34,827 - $52,856	4,732 Added 583.48%	5,543 $60,000
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $2,365 - $3,524	301 Added 59.02%	811 $7,000
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $17,579 - $63,544	-2,490 Reduced 83.0%	510 $4,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $164,943 - $254,977	-7,067 Reduced 70.2%	3,000 $71,000
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $93,121 - $195,962	5,282 Added 110.39%	10,067 $345,000
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $18,842 - $72,298	1,455 Added 43.69%	4,785 $85,000
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $85,148 - $149,450	3,330 New	3,330 $149,000

Others Institutions Holding PTGX

# of Institutions

299

Shares Held

61.4M

Call Options Held

1.01M

Put Options Held

555K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.19B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Protagonist Therapeutics, Inc Transaction History